New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape

Bibliography

• Centers for Disease Control and Prevention. Available from: www.cdc.gov [Cited 16 July 2014]
   Google Scholar
• Singh N, Kumar M, Singh RK. Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med 2012;5(6):485-97
   PubMed Web of Science ®Google Scholar
• Kamhawi S. Phlebotomine sand flies and Leishmania parasites: friends or foes? Trends Parasitol 2006;22(9):439-45
   PubMed Web of Science ®Google Scholar
• Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross-sectional surveys in the Gambia. Available from: http://www.who.int/
   Google Scholar
• WHO. Control of the leishmaniasis: report of a meeting of the WHO expert committee on the control of Leishmaniasis. World Health Organization; Geneva: 2010
   Google Scholar
• Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7(5):12
   Google Scholar
• Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol 2006;22(12):552-7
   PubMed Web of Science ®Google Scholar
• Boelaert M, Meheus F, Robays J, et al. Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis. Ann Trop Med Parasitol 2010;104(7):535-42
   PubMed Web of Science ®Google Scholar
• Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001;95(3):239-43
   PubMed Web of Science ®Google Scholar
• Weina PJ, Neafie RC, Wortmann G, et al. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis 2004;39(11):1674-80
   PubMed Web of Science ®Google Scholar
• Petersen CA. Leishmaniasis, an emerging disease found in companion animals in the United States. Top Companion Anim Med 2009;24(4):182-8
   PubMedGoogle Scholar
• Dujardin JC, Campino L, Canavate C, et al. Spread of vector-borne diseases and neglect of leishmaniasis. Europe. Emerg Infect Dis 2008;14(7):1013-18
   PubMed Web of Science ®Google Scholar
• Ready PD. Leishmaniasis emergence in Europe. Eurosurveillance 2010;15(10):29-39
   Google Scholar
• Frezard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules 2009;14(7):2317-36
   PubMed Web of Science ®Google Scholar
• van Griensven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am 2012;26(2):309-22
   PubMed Web of Science ®Google Scholar
• Palumbo E. Current treatment for cutaneous leishmaniasis: a review. Am J Ther 2009;16(2):178-82
   PubMedGoogle Scholar
• Alavi-Naini R FA, O’Dempsey T. Topical treatment modalities for old world cutaneous leishmaniasis: a review. Prague Med Rep 2012;113(2):105-18
   PubMedGoogle Scholar
• Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leish maniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005;5(12):763-74
   PubMed Web of Science ®Google Scholar
• Kobets T, Grekov I, Lipoldova M. Leishmaniasis: prevention, Parasite Detection and Treatment. Curr Med Chem 2012;19(10):1443-74
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, et al. Single-dose Liposomal Amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362(6):504-12
   PubMed Web of Science ®Google Scholar
• Khalil EAG, Weldegebreal T, Younis BM, et al. Safety and efficacy of single dose versus multiple doses of ambisome (r) for treatment of visceral leishmaniasis in eastern africa: a randomised trial. PLoS Negl Trop Dis 2014;8(1):e2613
   PubMed Web of Science ®Google Scholar
• Shukla AK, Singh BK, Patra S, et al. Rational approaches for drug designing against leishmaniasis. Appl Biochem Biotechnol 2010;160(8):2208-18
   PubMedGoogle Scholar
• Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011;377(9764):477-86
   PubMed Web of Science ®Google Scholar
• Kumar N, Sinha PK, Pandey K, et al. A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy. Int J Clin Pharm 2011;33(5):726-9
   PubMedGoogle Scholar
• Omollo R, Alexander N, Edwards T, et al. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials 2011;12:10
   PubMedGoogle Scholar
• Olliaro PL. Drug combinations for visceral leishmaniasis. Curr Opin Infect Dis 2010;23(6):595-602
   PubMedGoogle Scholar
• Barrett MP, Croft SL. Management of trypanosomiasis and leishmaniasis. Br Med Bull 2012;104(1):175-96
   PubMedGoogle Scholar
• Golgher D, Vianna CH, Moura AC. Drugs Against Leishmaniasis: overview of Market Needs and Pipeline. Drug Dev Res 2011;72(6):463-70
   Google Scholar
• Graybill JP. Lipid formulations for amphotericin B: Does the emperor need new clothes? Ann Intern Med 1996;124(10):921-3
   PubMedGoogle Scholar
• Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007;5(11):873-82
   PubMed Web of Science ®Google Scholar
• Hamill R, Amphotericin B. Formulations: a Comparative Review of Efficacy and Toxicity. Drugs 2013;73(9):919-34
   PubMed Web of Science ®Google Scholar
• Mohapatra S. Drug resistance in leishmaniasis: newer developments. Trop Parasitol 2014;4(1):4-9
   PubMedGoogle Scholar
• Tunac JB. Acea Biotech Inc. New polyene macrolide compounds useful for treating or inhibiting a fungal infection, preferably onychomycosis, and a parasitic infection, protozoal infection, leishmaniasis, and primary amebic meningoencephalitis. WO2012012782; 2012
   Google Scholar
• Powerful Anti-Fungal Drug. Available from: www.aceabiotech.com/corifungin
   Google Scholar
• Debnath A, Tunac JB, Galindo-Gomez S, et al. Corifungin, a New Drug Lead against Naegleria, Identified from a High-Throughput Screen. Antimicrob Agents Chemother 2012;56(11):5450-7
   PubMed Web of Science ®Google Scholar
• Debnath A, Tunac JB, Silva-Olivares A, et al. In Vitro Efficacy of Corifungin against Acanthamoeba castellanii Trophozoites and Cysts. Antimicrob Agents Chemother 2014;58(3):1523-8
   PubMed Web of Science ®Google Scholar
• Coelho EAF, Bento RWC, Valadares DG, et al. Univ Federal Minas Gerais, Minasfungi Brasil. Formulation used for preparing medicine for preventing and treating canine and human cutaneous and visceral leishmaniasis, comprises aqueous extract obtained from Agaricus blazei or its purified fractions and protein. WO2011140623; 2011
   Google Scholar
• Valadares DG, Duarte MC, Oliveira JS, et al. Leishmanicidal activity of the Agaricus blazei Murill in different Leishmania species. Parasitol Int 2011;60(4):357-63
   PubMed Web of Science ®Google Scholar
• Valadares DG, Duarte MC, Ramirez L, et al. Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis. Exp Parasitol 2012;132(2):228-36
   PubMedGoogle Scholar
• Valadares DG, Duarte MC, Ramirez L, et al. Therapeutic efficacy induced by the oral administration of Agaricus blazei Murill against Leishmania amazonensis. Parasitol Res 2012;111(4):1807-16
   PubMedGoogle Scholar
• Sobarzo SE, Martinez UF, Gonzalez DH, et al. Univ Complutense Madrid, Univ Santiago Compostela, Univ Cardenal Herrera-Ceu. Use of oxoisoaporphine derivatives, its pharmaceutically acceptable salts, hydrates, solvates, tautomers, stereoisomers and N-oxides, for the preparation of a medicament for the treatment of leishmaniasis patent. WO2013045730; 2013
   Google Scholar
• Sobarzo-Sanchez E, Bilbao-Ramos P, Dea-Ayuela M, et al. Synthetic oxoisoaporphine alkaloids: in vitro, in vivo and in silico assessment of antileishmanial activities. PLoS One 2013;8(10):8
   Google Scholar
• Honda P, Ferreira I, Amado C, et al. Efficacy of components from leaves of Calophyllum brasiliense against Leishmania amazonensis. Phytomedicine 2010;76(12):1309-9
   Google Scholar
• Univ Estadual de Maringá. Formulação tópica para o tratamento da leishmaniose. BRPI0904042-0; 2011
   Google Scholar
• Tiuman TS, Brenzan MA, Ueda-Nakamura T, et al. Intramuscular and topical treatment of cutaneous leishmaniasis lesions in mice infected with Leishmania amazonensis using coumarin (-) mammea A/BB. Phytomedicine 2012;19(13):1196-9
   PubMedGoogle Scholar
• Kimura J, Horie S, Marushima H, et al. Aoyama Gakuin Educational Found. New 5-ethyl-5-((2E,6E,10E)-3,7,11,15-tetramethyl-hexadeca-2,6,10,14-tetraenyl)-cyclohex-2-ene-1,4-dione compound useful for preparing drug for treating leishmaniasis. US8373006; 2013
   Google Scholar
• Rahman A, Choudhary M I, Yousuf S, et al. Composition, useful for treating leishmaniasis in warm blooded animals and humans, comprises ethyl acetate extract of aerial parts of Physalis minima dispersed in petroleum. US8287921; 2012
   Google Scholar
• Guimaraes ET, Lima MS, Santos LA, et al. Activity of physalins purified from Physalis angulata in in vitro and in vivo models of cutaneous leishmaniasis. J Antimicrob Chemother 2009;64(1):84-7
   PubMed Web of Science ®Google Scholar
• Nogueira RC, Rocha VPC, Nonato FR, et al. Genotoxicity and antileishmanial activity evaluation of Physalis angulata concentrated ethanolic extract. Environ Toxicol Pharmacol 2013;36(3):1304-11
   PubMedGoogle Scholar
• Kedzierski L, Sakthianandeswaren A, Curtis JM, et al. Leishmaniasis: current Treatment and Prospects for New Drugs and Vaccines. Curr Med Chem 2009;16(5):599-614
   PubMed Web of Science ®Google Scholar
• Univ North Carolina, Univ Georgia State Res Found Inc. New aza teraryl compound for treating microbial infection e.g. Trypanosoma brucei rhodesiense infection, Plasmodium falciparum infection, and Leishmania donovani infection. US7964619; 2011
   Google Scholar
• Tidwell RR, Brun R, Boykin DW, et al. Univ North Carolina, Univ Georgia State Res Found Inc. New aza teraryl compounds useful for treating microbial infection comprising Trypanosoma brucei rhodesiense, Plasmodium falciparum and Leishmania donovoni infection. US8188121; 2012
   Google Scholar
• Tidwell RR, Brun R, Boykin DW, et al. Univ North Carolina, Univ Georgia State Res Found Inc. New 2,5-diaryl-selenophene and 2,5-diaryl-thiophene compounds useful for treatment of infection caused by bacteria, fungi, algae, viruses or protozoa, e.g. by Plasmodium falciparum, or Mycobacterium tuberculosis. WO2009051796; 2009
   Google Scholar
• Univ North Carolina, Univ Georgia State Res Found Inc. Werbovetz K, et al. New dicationic bichalcophene compound for treating protozoal infection, e.g. Trypanosoma species infection in a subject, e.g. humans, cats, or dogs. EP1726589; 2006
   Google Scholar
• Roussaki M, Hall B, Lima SC, et al. Synthesis and anti-parasitic activity of a novel quinolinone-chalcone series. Bioorg Med Chem Lett 2013;23(23):6436-41
   PubMed Web of Science ®Google Scholar
• de Mello TFP, Bitencourt HR, Pedroso RB, et al. Leishmanicidal activity of synthetic chalcones in Leishmania (Viannia) braziliensis. Exp Parasitol 2014;136:27-34
   PubMedGoogle Scholar
• Rizvi SUF, Siddiqui HL, Ahmad MN, et al. Novel quinolyl-thienyl chalcones and their 2-pyrazoline derivatives with diverse substitution pattern as antileishmanial agents against Leishmania major. Med Chem Res 2012;21(7):1322-33
   Google Scholar
• Monga V, Goyal K, Steindel M, et al. Synthesis and evaluation of new chalcones, derived pyrazoline and cyclohexenone derivatives as potent antimicrobial, antitubercular and antileishmanial agents. Med Chem Res 2014;23(4):2019-32
   Web of Science ®Google Scholar
• Univ Louisville Res Found Inc., Ird Inst Rech Dev, Univ Johns Hopkins. New chalcone and benzothienopyrimidine compounds useful e.g. for treating cancer, leishmaniasis, Chagas disease, tuberculosis, malaria, helminth infectious diseases, trachoma, buruli ulcer, cholera, dengue and dracunculiasis. WO019861; 2010
   Google Scholar
• Univ Laguna. Control of leishmaniasis uses trans-chalcone (1,3 diphenyl-2-propene-2-one) as product obtained biogenetically from phenyl propane and acetate, characterized by having two aromatic rings joined by chain with carbonylic unsaturated system. ES2173017; 2004
   Google Scholar
• Dritte Patentportfolio Bet-GMBH&CO KG. New pentamidine derivatives useful for treating and/or prophylaxis of oncological diseases and tumors of any pathogenesis, leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia and malaria. WO014059; 2013
   Google Scholar
• Boechat N, Costa MS, Lourenco MCS, et al. Fundação Oswaldo Cruz. New 1,2,3-triazole or imidazole compounds useful for treating or inhibiting tuberculosis and leishmaniasis. US8436027; 2013
   Google Scholar
• Werbovetz K, Bhattacharya G, Sackett D, et al. Univ Ohio State, Us Nat Inst Of Health, Nat Inst Of Health Korea. New dinitroaniline sulfonamides useful in the treatment of e.g. visceral leishmaniasis, Chagas disease, human African trypanosomiasis, animal trypanosomiasis and malaria. WO2003090678; 2003
   Google Scholar
• Freitas-Junior LH, Chatelain E, Kim HA, et al. Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist 2012;2:11-19
   PubMed Web of Science ®Google Scholar
• Matoussi N, Ameur HB, Amor SB, et al. Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime (R)). A case report. Med Mal Infect 2007;37:S257-S59
   PubMedGoogle Scholar
• Gasser RA, Magill AJ, Oster CN, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994;18(1):83-90
   PubMed Web of Science ®Google Scholar
• Shahian M, Alborzi A. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children. Med Sci Monit 2009;15(6):CR290-CR93
   PubMedGoogle Scholar
• Zaghloul IY, Al-Jasser M. Effect of renal impairment on the pharmacokinetics of antimony in hamsters. Ann Trop Med Parasitol 2004;98(8):793-800
   PubMed Web of Science ®Google Scholar
• Cedeno-Medina DL, Vasquez LAR, Duque SM, et al. Univ Antioquia, Univ Illinois State, Univ Caldas. Use of quaternary N-(halomethyl) ammonium salts as therapeutic agents e.g. against Leishmania tarentolae parasites and axenic amastigotes of Leishmania panamensis and Leishmania amazonensis parasites, and to treat cutaneous leishmaniasis. WO2013179244; 2013
   Google Scholar
• Beilles S, Chambonnet S, Collaveri JP, et al. Sanofi. Hydro-alcoholic gel formulation used for treating leishmaniasis, particularly cutaneous leishmaniasis caused by Leishmania amazonensis strains, Leishmania donovani strains or Leishmania major strains, comprises dronedarone. WO2013182423; 2013
   Google Scholar
• Benaim G, Casanova P, Hernandez-Rodriguez V, et al. Dronedarone, an amiodarone analog with improved anti-leishmania mexicana efficacy. Antimicrob Agents Chemother 2014;58(4):2295-303
   PubMedGoogle Scholar
• Merial Ltd. Substantially or completely curing Leishmania parasite infection from an animal including canine, comprises step of administering fexinidazole to the animal. WO121064; 2014
   Google Scholar
• Wyllie S, Patterson S, Stojanovski L, et al. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med 2012;4(119):119re1
   PubMed Web of Science ®Google Scholar
• DNDi. Fexinidazole (VL). 2014. Available from: www.dndi.org/diseases-projects/portfolio/fexinidazole-vl.html
   Google Scholar
• Bhandari V, Kulshrestha A, Deep DK, et al. Drug susceptibility in leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis 2012;6(5):6
   Google Scholar
• Rai K, Cuypers B, Bhattarai NR, et al. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting leishmania donovani strain. Mbio 2013;4(5):4
   Google Scholar
• Ostyn B, Hasker E, Dorlo TPC, et al. Failure of miltefosine treatment for visceral leishmaniasis in children and men in south-east Asia. PLoS One 2014;9(6):8
   Google Scholar
• Fortin A, Hendrickx S, Yardley V, et al. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis. J Antimicrob Chemother 2012;67(11):2707-12
   PubMedGoogle Scholar
• Max Planck Ges Foerderung Wissenschaften. Use of oleyl-phosphocholine compound for preparing drug to treat e.g. leishmaniasis, ehrlichiosis, cancer, multiple sclerosis and/or psoriasis, protozoa diseases, Plasmodium diseases and bladder tumors. WO116641; 2008
   Google Scholar
• Dafra Pharma Res&Dev BVBA. Solid dosage form of oleyl phosphocholine, useful for treating parasitic diseases, preferably leishmaniasis, chagas or malaria, and cancer, comprises oleyl phosphocholine and fillers, disintegrants, binders, lubricants, and diluents. WO069427; 2012
   Google Scholar
• Dafra Pharma Res & Dev BVBA. Pharmaceutical composition useful for treating parasitic and skin diseases and cancer, preferably leishmaniasis comprises oleyl phosphocholine, and carriers and excipients e.g. stabilizers and nonionic surfactants. WO095500; 2012
   Google Scholar
• Hernandez L, Galvez R, Montoya A, et al. First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum. Parasitol Res 2014;113(1):157-64
   PubMedGoogle Scholar
• Monzote L. Antileishmanial patents antileishmanial current drugs and relevant patents. Recent Pat Antiinfect Drug Discov 2011;6(1):1-26
   PubMedGoogle Scholar
• Fuji Photo Film Co Ltd, Dana Farber Cancer Inst, Inc. Use of rhodacyanine dye-contg. compsn. - for treatment of cancer, especially carcinoma and melanoma. EP527494; 1996
   Google Scholar
• Japan Sci&Technology Agency (Jsta-C) Fuji Photo Film Co. Ltd, Univ Tohoku. Ihara M, Masataka I. Composition for preventing and treating protozoal diseases, such as malaria, leishmianiasis and American/African trypanosomiasis, contains aromatic compound as active ingredient. EP1800682; 2013
   Google Scholar
• Takasu K, Terauchi H, Inoue H, et al. Antileishmanial activities of rhodacyanine dyes. Heterocycles 2004;64:215-21
   Google Scholar
• Yang M, Arai C, Md AB, et al. Fluorinated Rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL). J Med Chem 2010;53(1):368-73
   PubMedGoogle Scholar
• Univ Hoshi, Fuji Film Corp. New rhodacyanine derivatives, useful for treating leishmaniasis including cutaneous leishmaniasis, visceral leishmaniasis and mucocutaneous leishmaniasis. WO046158; 2011
   Google Scholar
• Camarasa Rius MJ, Perez MJ, Malpica EC. Consejo Superior Investigaciones Cientif, Univ Alcala. New nucleoside derivatives used for preparing pharmaceutical composition containing pharmaceutically acceptable carrier for treating infectious diseases caused by Leishmania in humans or animals. ES2341603; 2011
   Google Scholar
• Entarco Sa, Kritikou C. Treating disorder or disease or condition in host or host tissue in need of an oxidative phosphorylation inhibitor, comprises administering to the host or host tissue, a composition comprising spinosyn or derivative or salt or prodrug. WO150100; 2010
   Google Scholar
• Kirst HA, Michel KH, Martin JW, et al. A83543A-D, Unique fermentation-derived tetracyclic macrolides. Tetrahedron Lett 1991;32(37):4839-42
   Google Scholar
• Council of Scientific & Industrial Research. Antileishmanial activity of amphotericin b entrapped in a cationic liposomal formulation. IN0670/DEL/2007’ 2007
   Google Scholar
• Duran JJT, Saldana HKR, Lopez RS, et al. Univ Complutense Madrid. Topical pharmaceutical formulation used for treating fungal infection (cutaneous and mucocutaneous mycoses) and parasitic infections (cutaneous leishmaniasis) in humans, comprises complex of monomeric amphotericin B and gamma-cyclodextrin. WO2012042072; 2012
   Google Scholar
• Ruiz HK, Serrano DR, Dea-Ayuela MA, et al. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp. Int J Pharm 2014;473(1-2):148-57
   PubMed Web of Science ®Google Scholar
• Duran JJT, Duran ST, Sanchez-Brunete JA, et al. Univ Complutense Madrid. Microspheres of albumin that include amphotericin B (I), useful for treatment of mycosis and parasitic infections, particularly visceral leishmaniosis, are less toxic than usual formulations. WO062645; 2004
   Google Scholar
• Balasegaram M, Ritmeijer K, Lima MA, et al. Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 2012;17(4):493-510
   PubMed Web of Science ®Google Scholar
• Dealbornoz AOC, Castanys S. Sopar NV SA. Treatment of protozoal parasitosis - using sub:microscopic particles of an alkyl cyanoacrylate. EP269598; 1991
   Google Scholar
• Domb AJ, Polacheck I, Soskolni M, et al. Hadasit Medical Res Services & Dev Ltd, Yissum Res Dev Co Hebrew Univ Jerusalem. New conjugate useful as antibiotic, antiparasitic or anticancer agent is prepared by reacting unmodified conjugate having aldehyde groups with reagent capable of chemically transforming aldehyde groups into groups e.g. amine, imine, amide. WO2007034495; 2007
   Google Scholar
• Rezende SA, Frezard FJG, Azevedo EG, et al. Fundação de Amparo a Pesquisa de Minas Gerais, Univ Federal Minas Gerais. Pharmaceutical composition used for producing medicament for treatment of visceral leishmaniasis in mammals, comprises combination of conventional liposomes and prolonged circulating liposomes incorporating antileishmanial drugs. WO2013131164; 2013
   Google Scholar
• Blanco-Prieto MJ, De Mendoza AEH, Martinez MAC, et al. Consejo Superior Investigaciones Cientif, Univ Navarra, Apointech Sl. Pharmaceutical composition used for preparing medicament for treating cancer, Hodgkin’s disease and leishmaniasis, comprises lipid nanoparticles with ether phospholipid and lipid. ES2388963; 2013
   Google Scholar
• Coelho EAF, Faraco AAG, Gomes TR, et al. Univ Federal Minas Gerais. Obtaining controlled volatile drug releasing multilayered film used in medicament preparation for treating leishmaniasis, involves using polymer dispersion of chitosan in aqueous organic acid and depositing dispersion in suitable container. WO2012139190; 2012
   Google Scholar